<DOC>
	<DOCNO>NCT02878642</DOCNO>
	<brief_summary>The main assumption dolutegravir get virologic suppression suboptimal adherence level ( 80 95 % , treatment interruption ) molecule capable , due pharmacokinetic/pharmacodynamic ( pardonnance ) . While investigator goal compare molecule ( study one arm ) term forgiveness , result cohort term forgiveness could compare cohort available .</brief_summary>
	<brief_title>Adherence Dolutegravir Outcome</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>HIV1 Age 18 year Information letter sign ART ( antiretroviral therapy ) least 3 active molecule Patients start treatment dolutegravir ( na√Øve antiretroviral treatment , switch , virologic failure ) pregnant woman HIV2 Patient responsibility observance treatment ( disorder judgment , guardianship , institutionalization ) Patient receive aid incompatible compliance use electronic pillbox</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>